Namodenoson
Phase 3Small molecule
Namodenoson is one of 111 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
110
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Namodenoson
CCan-Fite BioPharma
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Byetta
AstraZenecaPreclinical
Medrol
PfizerPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Alcoholic Steatohepatitis1 trial
Hepatocellular Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Namodenoson. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCan-Fite BioPharma